8-K: Mangoceuticals Clarifies Branded GLP-1 Program Access

Mangoceuticals clarifies its new weight-management programs offer access to FDA-approved branded GLP-1 medications like Zepbound and Wegovy through a third-party provider, not direct contracts with Eli Lilly or Novo Nordisk.

Summary

• Mangoceuticals, Inc. (MGRX) issued a press release on November 13, 2025, clarifying its prior announcement regarding the availability of branded GLP-1 weight-management programs.
• The newly launched Mangoceuticals weight-management programs, MangoRx Direct and PeachesRx Direct, are licensed and approved to issue valid prescriptions for FDA-approved branded GLP-1 medications, including Zepbound from Eli Lilly and Wegovy from Novo Nordisk, through a third-party provider.
• Patients receiving such prescriptions can fill them at any licensed pharmacy of their choice or through established channels like LillyDirect Self-Pay Pharmacy Solutions and NovoCare Pharmacy.
• Mangoceuticals explicitly states it has no direct contractual relationship with Eli Lilly or Novo Nordisk; access is facilitated by an independent third-party pharmacy benefits and access solutions provider.
• The MangoRx Direct and PeachesRx Direct programs are now live, offering telehealth consultations, personalized care plans, and ongoing support for $99 per month, with medication cost and fulfillment separate.
• MangoRx focuses on men's health and wellness products and services via a telemedicine platform, including erectile dysfunction, hair growth, hormone replacement therapies, and weight management.

Sentiment

Score: 7

Explanation: The filing clarifies a significant new service offering, providing a pathway for patients to access high-demand branded GLP-1 medications, which is a positive business development. However, the lack of direct contractual relationships with Eli Lilly or Novo Nordisk introduces a degree of indirectness in the access model, and the extensive list of general risks warrants a balanced perspective.

Positives

• Launch of new weight-management programs (MangoRx Direct and PeachesRx Direct) expands the company's service offerings into a high-demand market.
• Programs provide a pathway for patients to access FDA-approved branded GLP-1 medications (Zepbound and Wegovy), which are highly sought after.
• The telemedicine platform offers convenience with telehealth consultations, personalized care plans, and ongoing support for a monthly fee of $99.
• The company's medical operations and prescribing providers have been vetted and authorized by an independent third-party provider, aiming for reliable access to authentic medications.

Negatives

• Mangoceuticals has no direct contractual relationship with Eli Lilly or Novo Nordisk, relying on third-party providers for access to branded GLP-1 medications, which could introduce complexities or dependencies.
• The monthly program fee of $99 does not include the cost of medication and fulfillment, which are separate, potentially leading to higher overall costs for patients.
• Access to medications is subject to current manufacturer supply availability, which could pose a risk if supply chains are disrupted.

Risks

• Uncertainty of commercial success for new programs and product candidates.
• Reliance on third parties to conduct clinical trials, prescribe, compound products, and facilitate access to branded medications.
• Unexpected adverse side effects or inadequate therapeutic efficacy of drug candidates could limit approval/commercialization or result in recalls/product liability claims.
• Challenges and uncertainties inherent in product research and development, including clinical success and obtaining regulatory approvals.
• Manufacturing difficulties and delays.
• Competition, including technological advances, new products, and patents attained by competitors.
• Changes to applicable laws and regulations, including global healthcare reforms and trends toward healthcare cost containment.
• Potential lawsuits, claims, and actions, including those related to intellectual property.
• Ability to raise funding, the terms of such funding, and dilution caused thereby.
• Ability to meet and maintain Nasdaq listing requirements.
• Risks that the company's *other* products (not the branded GLP-1s) have not been, and will not be, approved by the U.S. Food and Drug Administration (FDA) and have not had the benefit of FDA clinical trial protocols.
• Risks that the FDA may determine that the compounding of the company's products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (FFDCA Act) provided by Section 503A.
• Risks associated with related party relationships and agreements, including significant reliance on related party transactions.
• The effect of data security breaches, malicious code, and/or hackers.
• Volatility in the trading price of the common stock.
• Macroeconomic, geopolitical, health, and industry trends, including inflation, interest rates, economic downturns, pandemics, and acts of war.

Future Outlook

The company aims to continue expanding its men's health and wellness telemedicine platform, now including a reliable pathway for patients to access FDA-approved branded GLP-1 medications for weight management. Future success will depend on the commercial adoption of these programs and the ability to navigate the competitive and regulatory landscape.

Management Comments

• Mangoceuticals aims to provide a reliable pathway for patients to obtain authentic branded GLP-1 medications from Eli Lilly and Novo Nordisk through established, publicly available channels via its new weight-management programs, MangoRx Direct and PeachesRx Direct.

Industry Context

The launch of these GLP-1 weight-management programs positions Mangoceuticals within the rapidly growing telemedicine and weight-loss medication markets. Demand for GLP-1 agonists like Zepbound and Wegovy is extremely high, leading many telehealth providers to offer access. The company's strategy to facilitate access through third-party providers, rather than direct pharmaceutical partnerships, is a common model in this competitive space, allowing smaller players to enter the market without extensive direct agreements.

Comparison to Industry Standards

• The filing does not provide specific financial or operational data that would allow for a direct, detailed comparison to industry benchmarks or specific comparable companies' projects and results at this time. The announcement focuses on a service launch clarification rather than performance metrics.

Legal Proceedings

• The company lists potential lawsuits, claims, and actions, including those related to intellectual property, as a general risk factor.

Related Party Transactions

• The company identifies risks associated with related party relationships and agreements, including significant reliance on related party transactions, as a general risk factor.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market expansion through new service offerings, but also exposure to risks associated with indirect partnerships and competition.
• Customers: Gain access to highly sought-after FDA-approved branded GLP-1 medications for weight management through a convenient telemedicine platform.
• Third-party providers: Benefit from increased business volume by facilitating prescriptions and access to medications for Mangoceuticals' patients.

Next Steps

• Continued operation and promotion of the MangoRx Direct and PeachesRx Direct weight-management programs.
• Ongoing efforts to expand men's health and wellness product and service offerings via the telemedicine platform.

Key Dates

Recommendation

The launch of weight-management programs offering access to branded GLP-1 medications like Zepbound and Wegovy is a strategic positive, tapping into a high-demand market. However, the clarification that Mangoceuticals has no *direct* contractual relationship with Eli Lilly or Novo Nordisk, relying instead on third-party providers, introduces a layer of operational and supply chain risk. While the $99/month subscription model offers a recurring revenue stream, the separate medication cost and the competitive landscape for GLP-1 access mean that sustained profitability and market share are not guaranteed. The extensive list of general risks, including funding, regulatory compliance for their *other* products, and reliance on third parties, suggests a 'hold' position until more concrete financial results from these programs and direct partnerships (if any) materialize.

Keywords

Mangoceuticals, MGRX, GLP-1, weight management, Zepbound, Wegovy, Eli Lilly, Novo Nordisk, telemedicine, telehealth, men's health, prescription, healthcare